PRP, cortisone, or gel injections for knee arthritis?
Compare three knee injection options by evidence, practical expectations, limitations, and coverage questions.
Read the guide ↗Medically reviewed by Charles A. DeCook, MD ·
← All optionsConsider individually
Gel shots / hyaluronic acid
Possible knee pain relief. Guidelines disagree.
What could it help with?
Gel shots may relieve knee arthritis pain for some people. Average benefit beyond a saline injection is small in the largest reviews, although some products and studies show more favorable results. Guidelines disagree about their use. They do not rebuild cartilage; discuss likely benefit, cost, risks, and any planned surgery with your clinician. [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15]
Who might it suit?
For: Selected knee OA after conservative care, with an honest evidence discussion.
Not for: Hip OA. Not a treatment to regrow cartilage.
Limits and important cautions
An average effect does not predict your response. Products and injection schedules differ. Knee findings should not be applied automatically to hip OA or other injectable gels, such as Arthrosamid. Symptom relief is not cartilage repair or proven prevention of replacement.
What happens, how long, and what could it cost?
- What happens
- One or a series of knee injections, depending on the exact product.
- When might I notice a change?
- For people who respond, improvement may take several weeks.
- How long might benefit last?
- Some responders report several months of relief. This is not a prediction for every patient.
- Repeat treatment
- Discuss whether the first course helped enough to justify another; schedules vary by product.
- Activity and recovery
- Ask about temporary limits on strenuous or weight-bearing activity and how to handle a painful, swollen knee.
- Ask for a complete estimate
- Exact product, number of injections, guidance, office fees, and repeat courses.
Use this as a consultation guide. A timeline is not a guarantee; the evidence and FDA sections below remain part of the decision.
Source for timing information ↗THE EVIDENCE IN CONTEXT
Mixed evidence; an individual knee-care decision
Read the 15 selected references
- Pereira et al.: viscosupplementation for knee OA ↗
Large placebo-controlled trials found an average pain benefit below the prespecified clinically important threshold. Individual response can differ.
- Altman et al.: Euflexxa FLEXX trial ↗
588 patients; three weekly injections. At 26 weeks, the adjusted pain difference was 6.6 points on a 100-point scale favoring Euflexxa. Both groups improved; this is a product-specific result.
- Migliorini et al.: hyaluronic acid molecular weights ↗
Higher-molecular-weight preparations had more favorable pain findings around four to six months. Indirect comparisons and variable products limit a universal ranking.
- Bruyère et al.: placebo-controlled HA evidence ↗
22 reviews: 20 found statistical benefits, but overall conclusions differed. Fourteen reviews were critically low quality; higher-quality reviews also disagreed about clinical value. Overlapping reviews are not independent trials.
- Nicholls et al.: disease severity and HA outcomes ↗
Findings were more favorable in early-to-moderate disease. Subgroups do not reliably identify individual responders. Funded by Ferring Pharmaceuticals.
- AAOS: nonsurgical knee OA care ↗
Knee-specific guidance; evidence strength varies by treatment. It should not be applied automatically to hip disease.
- ACR/Arthritis Foundation: OA management ↗
2019 guideline, published in 2020. Recommendations vary by joint; it predates many newer trials.
- NICE NG226: osteoarthritis care ↗
UK guidance on exercise, medicines, supports, and referral. Recommendations are not US coverage rules.
- OARSI: nonsurgical OA management ↗
Includes HA for selected knee OA patients depending on comorbidities; not recommended for hip or polyarticular OA.
- EUROVISCO: good practice recommendations ↗
Supports selected knee patients based on symptoms, disease severity, prior treatment and preferences. Consensus is not a randomized efficacy trial.
- Miller et al.: safety in more than 8,000 patients ↗
No statistically significant serious-adverse-event increase, but the confidence interval allowed increased risk. Several authors had manufacturer affiliations. This does not prove absence of harm.
- Synvisc-One: prescribing information ↗
Product-specific indication, injection reactions, contraindications and allergy precautions. Check the exact product; do not generalize all formulation details.
- Berkani et al.: time to knee replacement ↗
HA use was associated with approximately ten additional months before replacement. Confounding prevents a causal conclusion; this is not proof of cartilage preservation.
- Jones et al.: HA injections before knee replacement ↗
Found an association between HA within two months before replacement and infection. Observational findings do not establish a universal safe interval.
- Kurtz et al.: injections and replacement infection ↗
Did not find increased infection risk with injections within four months in the studied population. Conflicting observational results support individual surgical-team review.
FDA status
Approved devices · knee-specific labelsSeveral products are approved for knee OA pain. This is not a comparable hip indication.
Site summary of FDA information · reviewed September 19, 2026. Refer to current product labeling. This is not an FDA endorsement of this site.Will Medicare cover it?
Medicare often covers qualifying knee treatment after conservative care under local rules. Hip use is generally not covered.